TRAIL selectively induces apoptotic cell death in a variety of cancer cells and is regarded as a therapeutic apoptosis inducing treatment in some clinic trials, but TRAIL resistance is prevalent in many solid cancers including prostate cancer. The gene discussed is TNFSF10; the disease is cancer.